Agilent Technologies, Inc. (LON:0HAV)
105.88
-0.24 (-0.23%)
At close: Apr 25, 2025
Agilent Technologies Revenue
Agilent Technologies had revenue of $1.68B USD in the quarter ending January 31, 2025, with 1.39% growth. This brings the company's revenue in the last twelve months to $6.53B, down -3.00% year-over-year. In the fiscal year ending October 31, 2024, Agilent Technologies had annual revenue of $6.51B, down -4.73%.
Revenue (ttm)
$6.53B
Revenue Growth
-3.00%
P/S Ratio
4.33
Revenue / Employee
$364.97K
Employees
17,900
Market Cap
22.77B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Oct 31, 2024 | 6.51B | -323.00M | -4.73% |
Oct 31, 2023 | 6.83B | -15.00M | -0.22% |
Oct 31, 2022 | 6.85B | 529.00M | 8.37% |
Oct 31, 2021 | 6.32B | 980.00M | 18.36% |
Oct 31, 2020 | 5.34B | 176.00M | 3.41% |
Oct 31, 2019 | Pro | Pro | Pro |
Oct 31, 2018 | Pro | Pro | Pro |
Oct 31, 2017 | Pro | Pro | Pro |
Oct 31, 2016 | Pro | Pro | Pro |
Oct 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Agilent Technologies News
- 3 days ago - City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto - Seeking Alpha
- 3 days ago - Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission - GlobeNewsWire
- 3 days ago - Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025 - Business Wire
- 10 days ago - Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Business Wire
- 20 days ago - Tariffs And Tactics: Agilent's Path Through Trade Disruption - Seeking Alpha
- 24 days ago - Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today - Seeking Alpha
- 4 weeks ago - Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval - Business Wire
- 5 weeks ago - CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025 - Business Wire